1105689-83-5

Basic information

• Product Name: N-(3,4-difluorobenzyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide
• Synonyms: N-(3,4-difluorobenzyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide
• CAS NO: 1105689-83-5
• Molecular Weight: 377.371
• Mol File: 1105689-83-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(3,4-difluorobenzyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-difluorobenzyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide(1105689-83-5)
• EPA Substance Registry System: N-(3,4-difluorobenzyl)-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide(1105689-83-5)

Safety Data

• Hazardous Substances Data: 1105689-83-5(Hazardous Substances Data)

Upstream product

• 1105690-11-6 2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-N-(3,4-difluorobenzyl)-4-methylthiazole-5-carboxamide 
• 1105690-70-7 4-methyl-2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)thiazole-5-carboxylic acid 
• 1105690-63-8 ethyl 2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxylate 
• 22900-83-0 ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate 
• 53937-02-3 4-(benzyloxy)pyridin-2(1H)-one 
• 72235-53-1 3,4-difluorobenzylamine 

Relevant articles and documents

Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects

We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2-aminothiazole HTS hit by replacing the amide bond with a pyridinone moiety. Compound 19 demonstrated good potency against SCD1 in vitro and in vivo. The mouse liver microsomal SCD1 in vitro potency for 19 was improved by more than 240-fold compared to the original HTS hit. Furthermore, 19 demonstrated a dose-dependent reduction of plasma desaturation index with an ED50 of 6.3 mg/kg. Compound 19 demonstrated high liver to plasma and liver to eyelid exposures, indicating preferential liver distribution. The preliminary toxicology study with compound 19 did not demonstrate adverse effects related to SCD1 inhibition, suggesting a wide safety margin with respect to other known SCD1 inhibitors with wider distribution profiles.